What Vibrant does

Vibrant Therapeutics is a privately held, venture-backed biotechnology company founded in 2019 that develops conditional activation and targeted delivery multispecific antibody-based prodrugs for oncological, autoimmune, and neurological diseases. The company operates three proprietary platforms — BumbleBee (computational multi-specific antibody engineering), LogicBee (proteomics-based target identification), and NeuroBee (blood-brain-barrier delivery) — designed to work in concert to enable rational design of safer, more effective biotherapeutics. Its lead clinical program, VIB305, is a logic-gated, dual-targeting masked T-cell engager targeting EGFR-positive solid tumors, which received FDA IND acceptance in January 2026 and is being evaluated in clinical trials across the United States, Australia, and China.

The company is dual-headquartered in Cambridge, MA (United States) and Guangzhou, China, with a headcount of 51-100 employees. Leadership comprises Co-CEO & CTO Dr. Larry Wang and Co-CEO Dr. Han Lee (appointed January 2026), supported by SVPs covering antibody discovery, CMC, and operations, plus a dedicated BD lead. Vibrant's revenue model is pre-commercial biopharmaceutical development: it does not yet sell products, and revenue is expected to be generated through future drug commercialization or one-time licensing of assets and technologies, with partnerships actively solicited via [email protected]. The company has raised approximately $100 million in total capital, including a $61 million round in January 2026 that brought in Pfizer Ventures and Apricot Capital as new strategic investors alongside prior backers Bayland Capital, First Principle Venture, HSG, Northern Light Venture Capital, Matrix Partners China, and Redhill Capital.

The go-to-market posture is enterprise-oriented, combining clinical execution (trials run via CROs and medical institutions across three jurisdictions) with a partnership-led business development motion targeting strategic co-development or licensing counterparties in pharma. Customer concentration is by definition not yet observable, as no products are commercialized; the addressable base spans oncology, autoimmune, and CNS patient populations to be served either directly post-approval or through partner-led commercialization.

Name

Vibrant

Legal name

Vibrant Therapeutics

Website

https://vibrantx.com

Company type

Private

Founded year

2019

Operating status

Operating

Headcount range

51–100 employees

Short description

Vibrant Therapeutics is a clinical-stage biotech developing conditional activation, multispecific antibody-based prodrugs for oncology, autoimmune, and CNS diseases via three proprietary platforms (BumbleBee, LogicBee, NeuroBee), with lead program VIB305 advancing in U.S., Australian, and Chinese trials.

Ownership category

akta.pro rank

Product category

Biopharmaceutical Drug Development

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Bispecific & Multispecific Antibodies (HLAAAAAF)

akta.pro secondary industry

Monoclonal Antibody Therapeutics (mAbs) (HLAAAAAA)

Keywords

• Biotherapeutic drug development
• Antibody engineering platforms
• Oncology therapeutics pipeline
• Autoimmune disease drugs
• CNS drug delivery

Headquarters

HQ city

Guangzhou

HQ country

China

HQ region

Asia

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain

Revenue model

1. Biopharmaceutical Development: Developing biotherapeutics for oncological, autoimmune, and neurological diseases. Revenue will be generated through drug commercialization upon regulatory approval. Current programs include VIB305 for EGFR-positive solid tumors.

Go-to-market motion1 record

Marketing channels1 record

Core offering

Vibrant Therapeutics develops conditional activation and targeted delivery multispecific antibody-based prodrugs for oncological, autoimmune, and neurological diseases. Its offering is anchored by three proprietary platforms — BumbleBee (computational antibody engineering), LogicBee (proteomics-based target identification), and NeuroBee (blood-brain-barrier delivery) — and a lead clinical asset, VIB305, a logic-gated, dual-targeting masked T-cell engager for EGFR-positive solid tumors.

Product overview

Vibrant Therapeutics develops a unified portfolio of conditional activation and targeted delivery multispecific antibody-based prodrugs for oncological, autoimmune, and neurological diseases. The company's offerings center on VIB305, a lead program for EGFR-positive solid tumors, supported by three proprietary technology platforms: BumbleBee (computational multi-specific antibody engineering), LogicBee (proteomics-based target identification), and NeuroBee (blood-brain-barrier delivery). These platforms work together to enable rational design, precise disease targeting, and CNS delivery of biotherapeutics.

Differentiator

Problem solved

Functional benefit

Brands

• BumbleBee Platform: Advanced computing and multi-specific antibody engineering platform for streamlined biotherapeutic discovery
• LogicBee Platform
• NeuroBee Platform
• VIB305

Products and services

• VIB305 A logic-gated, dual-targeting masked T-cell engager for treatment of EGFR-positive solid tumors; Vibrant Therapeutics' lead clinical program, which received FDA IND acceptance and enables initiation of U.S. clinical studies.
• BumbleBee Platform Computational multi-specific antibody engineering platform that combines advanced computing with multi-specific antibody engineering to streamline biotherapeutic discovery and rational design. Offered to partners for collaboration regarding assets and technologies.
• LogicBee Platform Proteomics-based target identification platform that identifies key proteins differing between healthy and diseased tissues, enabling the design of biotherapeutics that precisely target diseases.
• NeuroBee Platform

Quantifiable outcome

• VIB305 (logic-gated, dual-targeting masked T-cell engager) received FDA IND acceptance

Segments3 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

One partnership is on record.

• Prospective PartnersminorStrategic or Co-development PartnerVibrant Therapeutics is open to partnerships and collaborations regarding assets and technologies. The company seeks strategic partners for co-development of biotherapeutics for oncological, autoimmune, and neurological diseases.

Scale indicators4 records

Recent moves6 records

Expansion highlights6 records

Market position

Strengths4 records

Competitive moat3 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/vibrantx

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds4 records

Investors8 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Vibrant